전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved231 programs
CGTLimited DatastaleKite, A Gilead CompanyPhase 1

anti-CD19 CAR-T (anti-CD19 CAR-T)

B-cell Adult Acute Lymphoblastic Leukemia; B-cell Chronic Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 2Status Active
CGTLimited DatastaleShanghai AbelZeta Ltd.Phase 1

A-CAR028 (A-CAR028)

Acute Myeloid Leukemia (AML); CAR-T Cell Therapy · Acute Myeloid Leukemia (AML)

#AcuteMyeloidLeukemiaAML#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleGoethe UniversityPhase 2

MabCampath (Alemtuzumab, Alemtuzumab (MabCampath))

Adult Acute Lymphocytic Leukemia T-cell; Lymphoma, Lymphoblastic · Adult Acute Lymphocytic Leukemia T-cell

#AdultAcuteLymphocyticLeukemiaT-c#Antibody#Phase2#monoclonal-antibody#Lymphoma+2
Trials 1Status Active
CGTLimited DatastaleAvenCell Europe GmbHPhase 1

Allo-RevCAR01-T (Allo-RevCAR01-T)

Acute Myeloid Leukemia, in Relapse; Acute Myeloid Leukemia Refractory · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleMustang Bio, Inc.Phase 1

Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes (Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes)

Adult Acute Myeloid Leukemia in Remission; Acute Biphenotypic Leukemia · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleBaylor College of MedicinePhase 1

Allogeneic CD5.CAR/28zeta CAR T cells (Allogeneic CD5.CAR/28zeta CAR T cells)

T-cell Acute Lymphoblastic Lymphoma; T-non-Hodgkin Lymphoma · T-cell Acute Lymphoblastic Lymphoma

#T-cellAcuteLymphoblasticLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleIRCCS Azienda Ospedaliero-Unive…Preclinical

Alloreactive NK cell infusion (Alloreactive NK cell infusion)

Adult Acute Myeloid Leukemia in Remission · Adult Acute Myeloid Leukemia in Remissio

#AdultAcuteMyeloidLeukemiainRemis#CGT#Preclinical#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleShenzhen Institute for Innovati…Phase 1

Anti-CD19-CAR transduced T cells (Anti-CD19-CAR transduced T cells)

Chronic Lymphocytic Leukemia; Acute Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleSumithira VasuPhase 1

Anti-CD19/CD20/CD22 CAR T-Cells (Anti-CD19/CD20/CD22 CAR T-Cells)

Recurrent Acute Lymphoblastic Leukemia; Recurrent B Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleSecond Affiliated Hospital, Sch…Phase 1

Anti-LILRA6 CAR-T cells (Anti-LILRA6 CAR-T cells)

Refractory Acute Myeloid Leukemia; Recurrent Acute Myeloid Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleRoswell Park Cancer InstitutePhase 1

Autologous Anti-CD83 CAR T-cells (Autologous Anti-CD83 CAR T-cells)

Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous BCMA/CD19 dual-target CAR-T module (Autologous BCMA/CD19 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous BCMA/CD38 dual-target CAR-T module (Autologous BCMA/CD38 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous BCMA/GPRC5D dual-target CAR-T (Autologous BCMA/GPRC5D dual-target CAR-T)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleInstitute of Hematology and Blo…Phase 1

Autologous CAR123 T lymphocytes (Autologous CAR123 T lymphocytes)

Leukemia, Myeloid, Acute(AML); Precursor Cell Lymphoblastic Leukemia-Lymphoma · Leukemia, Myeloid, Acute(AML)

#LeukemiaMyeloidAcuteAML#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleMustang Bio, Inc.Phase 1

Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes (Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes)

Adult Acute Myeloid Leukemia in Remission; Acute Biphenotypic Leukemia · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Phase 1

Autologous CD19-targeting CAR T cells (Autologous CD19-targeting CAR T cells)

Acute Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD19/CD20 dual-target CAR-T module (Autologous CD19/CD20 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD19/CD22 dual-target CAR-T module (Autologous CD19/CD22 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD33/CD123 dual-target CAR-T module (Autologous CD33/CD123 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD33

#CD33#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting

5 / 12 pages

← PreviousNext →